PCP or Claim characteristic†| Odds ratio | 95% CIs | P value |
---|---|---|---|
Medication class – inhaled steroid | 4.1 | 3.4-5.0 | <0.0001 |
E-prescribing with formulary decision support (FDS) usage | Â | ||
Low users (<30% of time) | 0.9 | 0.8-1.1 | 0.35 |
High users (>30% of time) | 0.8 | 0.6-1.1 | 0.16 |
Time periods | Â | ||
Non-interruptive FDS time period | 1.1 | 0.9-1.3 | 0.42 |
Interruptive and Non-interruptive FDS time period | 1.0 | 0.9-1.1 | 0.59 |
Interactions | Â | ||
Low users during time period with Non-interruptive FDS only | 0.9 | 0.6-1.5 | 0.74 |
Low users during time period with Interruptive and Non-interruptive FDS | 0.8 | 0.6-1.1 | 0.13 |
High users during time period with Non-interruptive FDS only | 0.9 | 0.4-2.3 | 0.83 |
High users during time period with Interruptive and Non-interruptive FDS‡ | 1.9 | 1.0-3.4 | 0.04 |